Antiapoptotic effect of ectopic TAL1/SCL expression in a human leukemic T-cell line

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2680-2687

  Bernard, Muriel ^a   Delabesse, Eric ^a   Novault, Sophie ^b   Hermine, Olivier ^a   Macintyre, Elizabeth A ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; METHOTREXATE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAL 1; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DNA-BINDING PROTEINS; ETOPOSIDE; HUMANS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032526246     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
2. Smets, L. A. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs, 5: 3-9, 1994.
3. Hickman, J. A. Apoptosis and chemotherapy resistance. Eur. J. Cancer, 32A: 921-926, 1996.
4. Hwang, L. Y., and Baer, R. J. The role of chromosome translocations in T cell acute leukemia. Curr. Opin. Immunol., 7: 659-664, 1995.
5. Robb, L., Rasko, J. E. J., Bath, M. L., Strasser, A., and Begley, C. G. scl, a gene frequently activated in human T cell leukaemia, does not induce lymphomas in transgenic mice. Oncogene, 10: 205-209, 1995.
6. Kelliher, M. A., Seldin, D. C., and Leder, P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase II α. EMBO J., 15: 5160-5166, 1996.
7. Condorelli, G. L., Facchiano, F., Valtieri, M., Proietti, E., Vitelli, L., Lulli, V., Huebner, K., Peschle, C., and Croce, C. M. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res., 56: 5113-5119, 1996.
8. Larson, R. C., Lavenir, L., Larson, T. A., Baer, R., Warren, A. J., Wadman, I., Nottage, K., and Rabbitts, T. H. Protein dimerization between Imo2 (Rbtn2) and tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J., 15: 1021-1027, 1996.
9. Aplan, P. D., Jones, C. A., Chervinsky, D. S., Zhao, X. F., Ellsworth, M., Wu, C. Z., McGuire, E. A., and Gross, K. W. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J., 16: 2408-2419, 1997.
10. Hsu, H. L., Huang, L., Tsan, J. T., Funk, W., Wright, W. E., Hu, J. S., Kingston, R. E., and Baer, R. Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins. Mol. Cell. Biol., 14: 1256-1265, 1994.
11. Bain, G., Engel, I., Robanus Maandag, E. C., te Riele, H. P., Voland, J. R., Sharp, L. L., Chun, J., Huey, B., Pinkel, D., and Murre, C. E2A deficiency leads to abnormalities in αβ T-cell development and to rapid development of T-cell lymphomas. Mol. Cell. Biol., 17: 4782-4791, 1997.
12. Mouthon, M. A., Bernard, O., Mitjavila, M. T., Romeo, P. H., Vainchenker, W., and Mathieumahul, D. Expression of tal-1 and GATA-binding proteins during human hematopoiesis. Blood, 81: 647-655, 1993.
13. Pulford, K., Lecointe, N., Leroyviard, K., Jones, M., Mathieumahul, D., and Mason, D. Y. Expression of TAL-1 proteins in human tissues. Blood, 85: 675-684, 1995.
14. Aplan, P. D., Nakahara, K., Orkin, S. H., and Kirsch, I. R. The SCL gene product: a positive regulator of erythroid differentiation. EMBO J., 11: 4073-4081, 1992.
15. Porcher, C., Swat, W., Rockwell, K., Fujiwara, Y., Alt, F. W., and Orkin, S. H. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell, 86: 47-57, 1996.
16. Robb, L., Elwood, N. J., Elefanty, A. G., Kontgen, F., Li, R., Barnett, L. D., and Begley, C. G. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J., 15: 4123-4129, 1996.
17. Leroy-Viard, K., Vinit, M. A., Lecointe, N., Jouault, H., Hibner, U., Romeo, P. H., and Mathieumahul, D. Loss of TAL-1 protein activity induces premature apoptosis of Jurkat leukemic T cells upon medium depletion. EMBO J., 14: 2341-2349, 1995.
18. Condorelli, G. L., Tocci, A., Botta, R., Facchiano, F. Testa, U., Vitelli, L., Valtieri, M., Croce, C. M., and Peschle, C. Ectopic TAL-1/SCL expression in phenotypically normal or leukemic myeloid precursors: proliferative and antiapoptotic effects coupled with a differentiation blockade. Mol. Cell. Biol., 17: 2954-2969, 1997.
19. Matsuo, Y., and Minowada, J. Human leukemia cell lines: clinical and theoretical significances. Hum. Cell. 1: 263-274, 1988.
20. Nicoletti, L, Migliorati, G., Paliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and cytometry. J. Immunol. Methods, 139: 271-279, 1991.
21. Schmid, I., Uittenbogaart, C. H., Keld, B., and Giorgi, J. V. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J. Immunol. Methods, 170: 145-157, 1994.
22. Darzynkiewicz, Z., Juan, G., Li, X., Gorczyca, W., Murakami, T., and Traganos, F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry, 27: 1-20, 1997.
23. Bernard, M., Smit, L., Macintyre, E., Matthieumahul, D., and Pulford, K. Nuclear localization of the SCL/TAL1 basic helix-loop-helix protein is not dependent on the presence of the basic domain. Blood, 85: 3356-3357, 1995.
24. Skladanowski, A., and Konopa, J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol., 46: 375-382, 1993.
25. Tsurusawa, M., Saeki, K., and Fujimoto, T. Differential induction of apoptosis on human lymphoblastic leukemia Nalm-6 and Molt-4 cells by various antitumor drugs. Int. J. Hematol., 66: 79-88, 1997.
26. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor of tumor necrosis factor. J. Exp. Med., 169: 1747-1756, 1989.
27. Begley, C. G., Aplan, P. A., Denning, S. M., Haynes, B. F., Waldmann, T. A., and Kirsch, I. R. The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc. Natl. Acad. Sci. USA, 86: 10128-10132, 1989.
28. Ono, Y., Fukuhara, N., and Yoshie, O. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL. J. Biol. Chem., 272: 4576-4581, 1997.
29. Breit, T. M., Mol, E. J., Wolverstettero, I. L. M., Ludwig, W. D., Vanwering, E. R., and Vandongen, J. J. M. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T-cell receptor α/β lineage: T-cell receptor-δ gene deletion mechanism affects multiple genes. J. Exp. Med., 177: 965-977, 1993.
30. Macintyre, E. A., Smit, L., Ritz, J., Kirsch, I. R., and Strominger, J. L. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor-αβ lineage. Blood, 80: 1511-1520, 1992.
31. Schlissel, M., Voronova, A., and Baltimore, D. Helix-loop-helix transcription factor E47 activates germ-line immunoglobulin heavy-chain gene transcription and rearrangement in a pre-T-cell line. Genes Dev., 5: 1367-1376, 1991.
32. Anderegg, B., Horstmann, M., and Kabisch, H. Effects of anti-tal-1 oligodeoxynucleotides in T-ALL cell lines. Cancer Gene Ther., 4: 84-90, 1997.
33. Goldfarb, A. N., Wolf, M. L., and Greenberg, J. M. Expression of a chimeric helix-loop-helix gene. Id-SCL, in K562 human leukemic cells is associated with nuclear segmentation. Am. J. Pathol., 141: 1125-1137, 1992.
34. Green, A. R., DeLuca, E., and Begley, C. G. Antisense SCL suppresses self-renewal and enhances spontaneous crythroid differentiation of the human leukaemic cell line K562. EMBO J., 10: 4153-4158, 1991.
35. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Natl. Med., 2: 574-547, 1996.
36. Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., and Kaufmann, S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90: 935-943, 1997.
37. Dubrez, L., Savoy, I., Hamman, A., and Solary, E. Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J., 15: 5504-5512, 1996.
38. Barry, M. A., Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
39. Del Bino, G., Skierski, J. S., and Darzynkiewicz, Z. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells. Exp. Cell Res., 195: 485-491, 1991.
40. Del Bino, G., Li, X., Traganos, F., and Darzynkiewicz, Z. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia (Baltimore), 8: 281-288, 1994.
41. Miyashita, T., and Reed, J. C. Bcl-2 oncoproiein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
42. L can differentially block chemotherapy-induced cell death. Blood. 90: 1208-1216, 1997.
43. L can confer a multidrug resistance phenotype. Blood, 86: 1903-1910, 1995.
44. L and Bcl-2 repress a common pathway of cell death. J. Exp. Med., 182: 821-828, 1995.
45. Datta, R., Banach, D., Kojima, H., Talanian, R. V., Alnemri, E. S., Wong, W. W., and Kufe, D. W. Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood, 88: 1936-1943, 1996.
46. Mashima, T., and Tsuruo, T. Involvement of ICE/CED 3 family proteases in antitumor agent-induced apoptosis (in Japanese). Gan To Kagaku Ryoho, 24: 211-215, 1997.
47. L function upstream of the CED-3-like apoptotic proteases. J. Biol. Chem., 271: 4573-4576, 1996.
48. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60: 23-32, 1996.
49. d variants. Br. J. Haematol., 99: 901-907, 1997.
50. Bash, R. O., Crist, W. M., Shuster, J. J., Link, M. P., Amylon, M., Pullen, J., Carroll, A. J., Buchanan, G. R., Smith, R. G., and Baer, R. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. Blood. 81: 2110-2117, 1993.
51. Bash, R. O., Hall, S., Timmons, C. F., Crist, W. M., Amylon, M., Smith, R. G., and Baer, R. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A Pediatric Oncology Group Study. Blood, 86: 666-676, 1995.